Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Merck And Eisai Partnered Phase 3 LITESPARK-011 Trial Of Oral Regimen Of Welireg (Belzutifan) Plus Lenvima (Lenvatinib) Met One Of Its Primary Endpoints Of Progression-free Survival For Advanced Renal Cell Carcinoma

Author: Benzinga Newsdesk | October 28, 2025 05:36am
  • First treatment regimen to demonstrate a statistically significant improvement in PFS for patients whose disease progressed following anti-PD-1/L1 therapy compared with cabozantinib in a Phase 3 study
  • LITESPARK-011 marks the first positive Phase 3 study of a HIF-2 alpha inhibitor in combination with a multi-targeted VEGF tyrosine kinase inhibitor

Posted In: MRK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist